New Developments in the Role of Lactobacillus Reuteri in Regulating Intestinal Barrier Function

doi:10.12114/j.issn.1007-9572.2021.02.123

Chinese General Practice ›› 2022, Vol. 25 ›› Issue (15): 1918-1922.DOI: 10.12114/j.issn.1007-9572.2021.02.123

• Review • Previous Articles

New Developments in the Role of Lactobacillus Reuteri in Regulating Intestinal Barrier Function

1. School of Health and Rehabilitation, Chengdu University of TCM, Chengdu 610075, China
2. Department of Rehabilitation Medicine, the General Hospital of Western Theater Command PLA, Chengdu 610083, China
3. Department of Rehabilitation Medicine, Shanghai Fourth People's Hospital Affiliated to Tongji University, Shanghai 200434, China

Received:2021-09-30 Revised:2021-11-30 Published:2021-12-02 Online:2022-04-07
Contact: Anren ZHANG
About author:
CEN Q Y, PANG R Z, HU X M, et al. New developments in the role of lactobacillus reuteri in regulating intestinal barrier function[J]. Chinese General Practice, 2022, 25 (15) : 1918-1922.

罗伊乳杆菌对肠屏障功能调节作用的研究进展

1. 610075　四川省成都市，成都中医药大学养生康复学院
2. 610083　四川省成都市，中国人民解放军西部战区总医院康复医学科
3. 200434　上海市，同济大学附属上海市第四人民医院康复医学科

通讯作者: 张安仁
作者简介:
岑秋宇，庞日朝，胡晓敏，等.罗伊乳杆菌对肠屏障功能调节作用的研究进展[J].中国全科医学，2022，25（15）：1918-1922. [www.chinagp.net] 作者贡献：岑秋宇提出研究选题方向，进行论文的构思与设计、文献及资料的整理，并撰写论文初稿；崔艳如负责检索和汇总文献及资料；胡晓敏对初稿进行修订；庞日朝、张安仁负责论文的质量控制及审校，对论文整体负责；所有作者确认了论文的最终稿。
基金资助:
国家自然科学基金面上项目(81973927)

Abstract

Abstract:

The intestinal barrier plays a role in maintaining the stability of the intestinal environment, which relies on the dynamic regulation of the intestinal microbiota. Lactobacillusreuteri (L.reuteri) is a lactic acid bacterium reported to be naturally present in the intestines of almost all vertebrates and mammals, and has been shown to affect the function of the intestinal barrier and safeguard the health of body through various pathways. This paper reviews the role and possible mechanisms of action of L.reuteri in regulating intestinal physical, chemical, immune and microbial barrier functions, with the aim of providing a theoretical basis and new ideas for the clinical application of L.reuteri in treating related diseases.

Key words: Gastrointestinal microbiome, Lactobacillus reuteri, Intestinal barrier, Review

摘要：

肠屏障维持着肠道内环境的稳定，其正常功能依赖于肠道微生物群的动态调控。罗伊乳杆菌（L.reuteri）是目前已报道的天然存在于绝大多数脊椎动物和哺乳动物肠道内的乳酸菌，已被证实可通过多种途径影响肠屏障功能，保障机体健康。本文综述了L.reuteri对肠机械、化学、免疫、微生物屏障功能的影响及可能机制，以期为L.reuteri在相关疾病的临床应用中提供一定的理论依据和新思路。

关键词: 胃肠道微生物组, 罗伊乳杆菌, 肠屏障, 综述

Qiuyu CEN,Rizhao PANG,Xiaomin HU, et al. New Developments in the Role of Lactobacillus Reuteri in Regulating Intestinal Barrier Function[J]. Chinese General Practice, 2022, 25(15): 1918-1922. DOI: 10.12114/j.issn.1007-9572.2021.02.123.
岑秋宇,庞日朝,胡晓敏等. 罗伊乳杆菌对肠屏障功能调节作用的研究进展[J]. 中国全科医学, 2022, 25(15): 1918-1922. DOI: 10.12114/j.issn.1007-9572.2021.02.123.

Figures/Tables 1

References 36

[1]	CARDOSO-SILVA D, DELBUE D, ITZLINGER A，et al. Intestinal barrier function in gluten-related disorders[J]. Nutrients，2019，11（10）：E2325. DOI：10.3390/nu11102325.
[2]	O'CONNOR G, JEFFREY E, MADORMA D，et al. Investigation of microbiota alterations and intestinal inflammation post-spinal cord injury in rat model[J]. J Neurotrauma，2018，35（18）：2159-2166. DOI：10.1089/neu.2017.5349.
[3]	CHOI W, YERUVA S, TURNER J R. Contributions of intestinal epithelial barriers to health and disease[J]. Exp Cell Res，2017，358（1）：71-77. DOI：10.1016/j.yexcr.2017.03.036.
[4]	SCHUMANN M, SIEGMUND B, SCHULZKE J D，et al. Celiac disease：role of the epithelial barrier[J]. Cell Mol Gastroenterol Hepatol，2017，3（2）：150-162. DOI：10.1016/j.jcmgh.2016.12.006.
[5]	MONTGOMERY T L, KÜNSTNER A, KENNEDY J J，et al. Interactions between host genetics and gut microbiota determine susceptibility to CNS autoimmunity[J]. Proc Natl Acad Sci USA，2020，117（44）：27516-27527. DOI：10.1073/pnas.2002817117.
[6]	WALTER J, BRITTON R A, ROOS S. Host-microbial symbiosis in the vertebrate gastrointestinal tract and the Lactobacillus reuteri paradigm[J]. PNAS，2011，108（Suppl 1）：4645-4652. DOI：10.1073/pnas.1000099107.
[7]	MU Q, TAVELLA V J, LUO X M. Role of Lactobacillus reuteri in human health and diseases[J]. Front Microbiol，2018，9：757. DOI：10.3389/fmicb.2018.00757.
[8]	KANDLER O, STETTER K O, KÖHL R. Lactobacillus reuteri sp. nov.，a new species of heterofermentative lactobacilli[J]. Zentralblatt Für Bakteriologie: I. Abt. Originale C: Allgemeine，Angewandte Und Ökologische Mikrobiologie，1980，1（3）：264-269. DOI：10.1016/S0172-5564(80)80007-8.
[9]	GREIFOVÁ G, MÁJEKOVÁ H, GREIF G，et al. Analysis of antimicrobial and immunomodulatory substances produced by heterofermentative Lactobacillus reuteri[J]. Folia Microbiol （Praha），2017，62（6）：515-524. DOI：10.1007/s12223-017-0524-9.
[10]	PETERSON L W, ARTIS D. Intestinal epithelial cells：regulators of barrier function and immune homeostasis[J]. Nat Rev Immunol，2014，14（3）：141-153. DOI：10.1038/nri3608.
[11]	LI L Z, FANG Z F, LIU X Y，et al. Lactobacillus reuteri attenuated allergic inflammation induced by HDM in the mouse and modulated gut microbes[J]. PLoS One，2020，15（4）：e0231865. DOI：10.1371/journal.pone.0231865.
[12]	GU Q, ZHANG C, SONG D，et al. Enhancing vitamin B12 content in soy-yogurt by Lactobacillus reuteri[J]. Int J Food Microbiol，2015，206：56-59. DOI：10.1016/j.ijfoodmicro.2015.04.033.
[13]	WANG M J, WU H Q, LU L H，et al. Lactobacillus reuteri promotes intestinal development and regulates mucosal immune function in newborn piglets[J]. Front Vet Sci，2020，7：42. DOI：10.3389/fvets.2020.00042.
[14]	WANG G, HUANG S, CAI S，et al. Lactobacillus reuteri ameliorates intestinal inflammation and modulates gut microbiota and metabolic disorders in dextran sulfate sodium-induced colitis in mice[J]. Nutrients，2020，12（8）：E2298. DOI：10.3390/nu12082298.
[15]	DROLIA R, BHUNIA A K. Crossing the intestinal barrier via Listeria adhesion protein and internalin A[J]. Trends Microbiol，2019，27（5）：408-425. DOI：10.1016/j.tim.2018.12.007.
[16]	WU H, XIE S, MIAO J，et al. Lactobacillus reuteri maintains intestinal epithelial regeneration and repairs damaged intestinal mucosa[J]. Gut Microbes，2020，11（4）：997-1014. DOI：10.1080/19490976.2020.1734423.
[17]	HOU Q, YE L, LIU H，et al. Lactobacillus accelerates ISCs regeneration to protect the integrity of intestinal mucosa through activation of STAT3 signaling pathway induced by LPLs secretion of IL-22[J]. Cell Death Differ，2018，25（9）：1657-1670. DOI：10.1038/s41418-018-0070-2.
[18]	MORRISON D J, PRESTON T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism[J]. Gut Microbes，2016，7（3）：189-200. DOI：10.1080/19490976.2015.1134082.
[19]	HE Q L, HAN C P, HUANG L，et al. Astragaloside IV alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation[J]. J Cell Mol Med，2020，24（16）：9349-9361. DOI：10.1111/jcmm.15586.
[20]	YANG S, YU M. Role of goblet cells in intestinal barrier and mucosal immunity[J]. J Inflamm Res，2021，14：3171-3183. DOI：10.2147/jir.s318327.
[21]	NATIVIDAD J M, VERDU E F. Modulation of intestinal barrier by intestinal microbiota：pathological and therapeutic implications[J]. Pharmacol Res，2013，69（1）：42-51. DOI：10.1016/j.phrs.2012.10.007.
[22]	XIE S, ZHAO S Y, JIANG L，et al. Lactobacillus reuteri stimulates intestinal epithelial proliferation and induces differentiation into goblet cells in young chickens[J]. J Agric Food Chem，2019，67（49）：13758-13766. DOI：10.1021/acs.jafc.9b06256.
[23]	田志梅，鲁慧杰，邓盾，等. 罗伊氏乳酸杆菌LR1对猪蛋白消化酶基因表达、肌肉抗氧化指标及氨基酸组成的影响[J]. 中国畜牧兽医，2021，48（6）：2045-2055. DOI：10.16431/j.cnki.1671-7236.2021.06.017.
[24]	MARTENS E C, NEUMANN M, DESAI M S. Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier[J]. Nat Rev Microbiol，2018，16（8）：457-470. DOI：10.1038/s41579-018-0036-x.
[25]	XIE W, SONG L, WANG X，et al. A bovine lactoferricin-lactoferrampin-encoding Lactobacillus reuteri CO21 regulates the intestinal mucosal immunity and enhances the protection of piglets against enterotoxigenic Escherichia coli K88 challenge[J]. Gut Microbes，2021，13（1）：1956281. DOI：10.1080/19490976.2021.1956281.
[26]	HE B K, HOANG T K, TIAN X J，et al. Lactobacillus reuteri reduces the severity of experimental autoimmune encephalomyelitis in mice by modulating gut microbiota[J]. Front Immunol，2019，10：385. DOI：10.3389/fimmu.2019.00385.
[27]	ANDRADE M E, ARAÚJO R S, DE BARROS P A，et al. The role of immunomodulators on intestinal barrier homeostasis in experimental models[J]. Clin Nutr，2015，34（6）：1080-1087. DOI：10.1016/j.clnu.2015.01.012.
[28]	WANG P, LI Y, XIAO H，et al. Isolation of Lactobacillus reuteri from Peyer's patches and their effects on SIgA production and gut microbiota diversity[J]. Mol Nutr Food Res，2016，60（9）：2020-2030. DOI：10.1002/mnfr.201501065.
[29]	GOMES A C, HOFFMANN C, MOTA J F. The human gut microbiota：metabolism and perspective in obesity[J]. Gut Microbes，2018，9（4）：308-325. DOI：10.1080/19490976.2018.1465157.
[30]	MOWAT A M, AGACE W W. Regional specialization within the intestinal immune system[J]. Nat Rev Immunol，2014，14（10）：667-685. DOI：10.1038/nri3738.
[31]	BACH KNUDSEN K E, LÆRKE H N, HEDEMANN M S，et al. Impact of diet-modulated butyrate production on intestinal barrier function and inflammation[J]. Nutrients，2018，10（10）：E1499. DOI：10.3390/nu10101499.
[32]	SINGH N, GURAV A, SIVAPRAKASAM S，et al. Activation of Gpr109a，receptor for niacin and the commensal metabolite butyrate，suppresses colonic inflammation and carcinogenesis[J]. Immunity，2014，40（1）：128-139. DOI：10.1016/j.immuni.2013.12.007.
[33]	CERVANTES-BARRAGAN L, CHAI J N, TIANERO M D，et al. Lactobacillus reuteri induces gut intraepithelial CD4⁺ CD8αα⁺ T cells[J]. Science，2017，357（6353）：806-810. DOI：10.1126/science.aah5825.
[34]	SERGEEV I N, ALJUTAILY T, WALTON G，et al. Effects of synbiotic supplement on human gut microbiota，body composition and weight loss in obesity[J]. Nutrients，2020，12（1）：E222. DOI：10.3390/nu12010222.
[35]	WAN Y, WANG F L, YUAN J H，et al. Effects of dietary fat on gut microbiota and faecal metabolites，and their relationship with cardiometabolic risk factors：a 6-month randomised controlled-feeding trial[J]. Gut，2019，68（8）：1417-1429. DOI：10.1136/gutjnl-2018-317609.
[36]	KIM C S, CHA L N, SIM M，et al. Probiotic supplementation improves cognitive function and mood with changes in gut microbiota in community-dwelling older adults：a randomized，double-blind，placebo-controlled，multicenter trial[J]. J Gerontol A Biol Sci Med Sci，2021，76（1）：32-40. DOI：10.1093/gerona/glaa090.

New Developments in the Role of Lactobacillus Reuteri in Regulating Intestinal Barrier Function

罗伊乳杆菌对肠屏障功能调节作用的研究进展

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 36

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	TIAN Chen, LIU Jianing, TIAN Jinhui, GE Long. Living Systematic Reviews: Methods and Processes for Development [J]. Chinese General Practice, 2025, 28(30): 3853-3860.
[2]	WANG Tingting, TANG Yong, ZHANG Wenke, LI Zhigang. Research Progress on Exercise Intervention of Hyperuricemia [J]. Chinese General Practice, 2025, 28(30): 3841-3846.
[3]	ZHOU Sheng, DENG Changsheng, ZOU Guanyang, SONG Jianping. Research Progress on the Pathogenesis of Complications of Malaria in Cardiovascular Diseases [J]. Chinese General Practice, 2025, 28(27): 3466-3472.
[4]	HUANG Yulin, WANG Haoyun, LI Yanmei, XIAO Xueying. Symptom Clusters in Gastric Cancer Patients Receiving Chemotherapy: a Scoping Review [J]. Chinese General Practice, 2025, 28(26): 3338-3344.
[5]	LIU Yinyin, SUI Hongping, LI Tingting, JIANG Tongtong, SHI Tieying, XIA Yunlong. Advances in Risk Prediction Models for Cardiotoxicity Associated with Breast Cancer Treatment [J]. Chinese General Practice, 2025, 28(24): 3072-3078.
[6]	LI Miaoxiu, ZHU Bowen, KONG Lingjun, FANG Min. Progress in Research on Clinical Assessment Tools for Conservative Treatment of Adolescent Idiopathic Scoliosis [J]. Chinese General Practice, 2025, 28(24): 3079-3088.
[7]	XIAO Yao, WAN Jun. Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants [J]. Chinese General Practice, 2025, 28(24): 3066-3071.
[8]	RUAN Wanbai, LI Junfeng, YIN Yanmei, PENG Lei, ZHU Kexiang. Research Progress of Targeted Therapy and Immunotherapy for Pancreatic Cancer [J]. Chinese General Practice, 2025, 28(23): 2950-2960.
[9]	ZHOU Lianpeng, LI Weifeng, DONG Xingang, WANG Xiaoyuan. Research Progress on the Role of Copper Homeostasis Regulation Mechanism in Cognition Disorder [J]. Chinese General Practice, 2025, 28(23): 2941-2949.
[10]	DONG Haocheng, HAO Xiao, AN Dong, LI Haohan, LI Shuren. Research Progress of Heart Failure with Supra-normal Ejection Fraction [J]. Chinese General Practice, 2025, 28(21): 2692-2696.
[11]	DU Qiongliang, LIN Bailang, GUO Honghua. Research Progress and Implications of Group Well-child Care [J]. Chinese General Practice, 2025, 28(21): 2672-2678.
[12]	WEN Yongxia, SUN Hai, CHEN Xiaoju, CAI Wanjing, LI Shuni, GUO Honghua. A Systematic Review of the Assessment Tools for Maternal Psychological Birth Trauma [J]. Chinese General Practice, 2025, 28(20): 2555-2561.
[13]	CHU Tianyu, GU Yan. Carotid Artery Calcification Features in Plaque Stability and Clinical Events [J]. Chinese General Practice, 2025, 28(18): 2247-2252.
[14]	ZHU Ziyi, HE Guixin, QIN Weibin, SONG Hui, ZHANG Liwen, TANG Weizhi, YANG Feifei, LIU Lingyun, OUYANG Bin. Research Progress of Mitochondrial Autophagy in Improving Myocardial Fibrosis after Myocardial Infarction and Intervention of Traditional Chinese Medicine [J]. Chinese General Practice, 2025, 28(18): 2294-2300.
[15]	TAN Wenbin, LI Jia, LIU Mingyu, LU Yongxin, CHENG Yaxin. Research Progress on the Influence of Nervous System Diseases and Related Therapeutic Drugs on Osteoporosis [J]. Chinese General Practice, 2025, 28(17): 2092-2100.